Overview

Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery

Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Compare the corneal penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing penetrating keratoplasty (PK)
Phase:
Phase 4
Details
Lead Sponsor:
Santen Inc.
Collaborator:
Vistakon Pharmaceuticals
Treatments:
Fluoroquinolones
Levofloxacin
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Ofloxacin
Ophthalmic Solutions
Pharmaceutical Solutions